

Is brace necessary after cervical surgery A meta-analysis of randomized controlled trials

Yang Mao, MD^a, Zhao Jindong, MD^{a,b,c,d}, Fang Zhaohui, PhD^{a,c,d,*}

Abstract

Background: Currently, there are increasing surgical treatments for neck pain. However, whether to use cervical brace after operation remains poorly defined. We aim to clear the clinical efficacy of the use of cervical brace after cervical surgery.

Methods: We searched for relevant studies in 8 electronic databases up to March 2021. The mean difference and 95% confidence intervals were used for continuous data. Cochrane Collaboration's tool was used to assess the risk of bias. The data were collected and input into the Review Manager 5.3 software (The Cochrane Collaboration, Copenhagen, Denmark).

Results: Four randomized controlled trials were finally included in our study. For pain, the pooled analysis showed that postoperative neck brace compared with no brace can relieve neck pain at all follow-up periods except 6 months. For neck disability index, the result showed that postoperative neck brace compared with no brace can improve neck disability index during the 3 to 12 month follow-up period. However, no significant difference was identified between 2 groups within the follow-up of 6 weeks after surgery. In addition, the result tends to get the opposite at follow-up of 24 months. For 36-Short form health survey Physical Component Summary, there was no significant difference between 2 groups in the early 3 weeks after surgery, but the results were changed after 3 weeks. For 36-short form health survey Mental Component Summary, there appears to be no significant change between 2 groups at all time intervals.

Conclusion: Wearing a cervical brace after cervical surgery is conducive to improving symptoms after cervical surgery at different stages. However, there is no relevant evidence indicating it can improve the mental health of postoperative patients. Higher quality, large prospective randomized studies are needed to verify the current conclusions.

Abbreviations: CBM = China Biology Medicine, CI = confidence interval, CNKI = Chinese National Knowledge Infrastructure, GRADE = Grading of Recommendations Assessment, Development, and Evaluation, MCID = minimal clinical important difference, MCS = Mental Component Summary scale, MD = mean difference, NDI = neck disability index, PCS = Physical Component Summary scale, RCTs = Randomized controlled trials, SD = standard deviation, SF-12 = 12-Short form health survey, SF-36 = 36-Short form health survey, VAS = Visual Analog Scale.

Keywords: cervical brace, meta-analysis, postoperative cervical spine

1. Introduction

Neck pain, causing pain and disability, is a common condition in the present climate.^[1] As ranked 19th overall in the global cause of disability-adjusted life years, it has brought a great economic burden to society.^[1,2] According to the Global Burden of Disease 2010 Study, neck pain is the fourth greatest contributor to global disability, ranking behind back pain, depression, and arthralgias.^[3] Treatment options for neck pain include conservative and surgical measures. In addition, conservative treatment is a reasonable treatment choice for nonneuropathic neck pain.^[4] While surgical management can be beneficial to patients with cervical radiculopathy or myelopathy that had failed a course of nonoperative methods.^[5] Numerous studies^[6–9] have shown that cervical surgery can effectively alleviate the pain and symptoms of patients and improve functional activities. However, about 22% of patients will have postoperative complications such as loss of height of the intervertebral space, displacement of the implant, and decreased fusion rate.^[10–12] Hence, the cervical brace is often used after cervical surgery to improve the above complications.^[11,13,14]

The use of cervical brace during postoperative period is commonly based on the belief that it may include the restriction of neck movement, providing spinal stability, reducing pain, and even increasing sense of security for patients.^[14–18] However, there is still no consensus regarding the use of cervical brace

How to cite this article: Yang M, Zhao J, Fang Z. Is brace necessary after cervical surgery: A meta-analysis of randomized controlled trials. Medicine 2022;101:27(e29791).

Received: 13 August 2021 / Received in final form: 19 May 2022 / Accepted: 25 May 2022

http://dx.doi.org/10.1097/MD.000000000029791

This project was supported by grants from the National Natural Science Foundation of China 81774286, Anhui University Collaborative Innovation Fund (GXXT-2020-025), and Local projects of central government transfer payment in 2021 (2021-36).

Consent for publication has been received.

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article.

^a The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China, ^b Anhui University of Traditional Chinese Medicine, Hefei, China, ^c Diabetes Institute, Anhui Academy of Chinese Medicine, Hefei, China, ^d Key Laboratory of Xin'an Medicine, Ministry of Education, Hefei, China

^{*}correspondence: Zhaohui Fang, Department of Endocrinology, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China (e-mail: fzhahszyy@163.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

after cervical spine surgery. Several studies^[14,19] reported that cervical brace treatment was recommended for postoperative patients of cervical spine because of better relief of symptoms. Nevertheless, some studies^[20,21] suggested the postoperative treatment with brace immobilization was not inferior to those without brace immobilization. In addition, to the best of our knowledge, no clinical guidelines concerning the use of cervical brace after cervical spine surgery have been found.

The controversy surrounding the efficacy of cervical brace after surgery demonstrates the need for further exploration of the effects of cervical brace use following surgery. There are no published quantitative meta-analyses, which are often used to provide scientific guidance for clinical practice, investigating if the use of cervical brace actually improves postoperative clinical outcomes. Therefore, this meta-analysis was to evaluate the existing literature about the use of postoperative cervical brace to determine the strength of evidence.

2. Materials and methods

This article was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement.^[22] Besides, it was based on previously conducted studies. Thus, no ethical approval and patient consent are required. The review protocol was registered with the International Prospective Register of Systematic Reviews registration, available online: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019121778.

2.1. Search strategy and selection criteria

As with the original review, we used the search strategies recommended by the Cochrane Back Review Group for the identification of randomized controlled trials (RCTs).^[23] An independent review of the Pubmed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure Database, Wanfang database, China Biology Medicine, and VIP database was performed from inception to March 2021. There were no limits on study dates or any language, publication type, and status restrictions. The search was conducted with the following keywords: cervical surgery (replacement, prosthesis, fusion, decompression, discectomy, laminoplasty, ablation, and endoscope) and cervical orthoses (cervical gear, cervical collar, cervical splints, cervical support, cervical brace, cervical bracing, cervical orthoses, and cervical orthosis). Different search strategies were used for Chinese and English language databases. To identify trials that may not have been published in full or were missed through the electronic search, we manually searched all references from the included studies and relevant previous systematic reviews.

The retrieved literature was screened by 2 independent investigators to evaluate eligibility, and any discrepancies were settled by discussion and consensus. Studies that met the following criteria were included in the analysis: Patients: suffering from cervical surgeries, including anterior cervical discectomy and fusion, cervical laminoplasty, cervical disc replacement, cervical decompression, cervical endoscope, etc.; Intervention: external cervical immobilization; Control: without external cervical immobilization; Primary outcome: neck pain; and Study style: prospective RCTs. The excluded studies were excluded due to the following reasons: studies do not conform to the above criteria; studies were in the form of letters, abstracts, reviews, or comments; and studies were impossible to extract relevant data.

2.2. Data extraction

Two reviewers independently extracted several data using a predesigned data extraction form, and the results were compared to avoid bias from the data extraction process. The following characteristic information was extracted from each study: design (the name of the first author, year of publication, and country), participants (sample size, age, gender of patients, disease, and surgical method), interventions (external cervical brace type, and intervention period), and outcomes (neck pain, neck disability index [NDI], and 36-Short form health survey [SF-36]). When relevant data had not been reported, we contacted the authors by email or in other ways to attempt to obtain the missing information.

2.3. Assessment of risk of bias

We assessed the study quality of each included trial according to the Cochrane risk of bias tool for randomized trials.^[24] We assessed the following items: the generation for random sequence, concealment for allocation sequence, blinding of participants, incomplete outcome data, selective outcome reporting, and other sources of bias. For each included study, each type of bias was rated as high, low, or unclear and entered into the risk of bias table. The risk of bias was examined by 2 reviewers concurrently, and discrepancies were resolved by consensus.

2.4. Outcome measures

The 3 most recommended outcome indicators, which are Visual Analog Scale; NDI, 36-Short form health survey (SF-36), or 12-Short form health survey, in the guidelines on cervical radiculopathy issued by the North American Spine Society were selected as outcome indicators. In addition, the pain was the main outcome, and the secondary outcomes were NDI, SF-36, or 12-Short form health survey.

2.5. Grading the quality of evidence

We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) (McMaster University, 2015) method to assess the quality of the evidence for each outcome of meta-analysis. Levels of quality of evidence were defined as high(++++), moderate(+++), low(++), and very low(+).^[25] We took into account the following items: risk of bias, inconsistency, indirectness, imprecision, and publication bias, and we operated on this web page: https://gradepro.org/.

2.6. Data synthesis and statistical analysis

We used DerSimonian and Laird random effects models in RevMan 5.3 (Nordic Cochrane Centre, Rigshospitalet, København, Denmark) to conduct the meta-analyses. The outcomes of interest only include continuous variables. We used mean difference (MD) to assess the difference in the continuous outcomes between the groups. Study weights were generated using the inverse of the variance. We present results as MD and associated 95% confidence intervals (CIs). In order to evaluate the sensibility of the meta-analysis, we excluded trials at high risk of bias. The significance threshold was a 2-sided P < 0.05. The forest plot for each parameter was constructed to illustrate the weight ratio of each incorporated study to evaluate potential publication bias if enough studies are included. We also used the GRADE approach to rate the quality of evidence and generate absolute estimates of effect for the outcome.^[26] Furthermore, the within-subject change standard deviation, which was calculated based on means and standard deviations at baseline and follow-up provided in articles, was required for the meta analysis.^[25] Thus, weighted by the sample size of each trial:

$$\begin{split} SD_{(follow-up-baseline)} &= \sqrt{SD^2{}_{baseline} + SD^2{}_{follow-up}} \\ &- (2 \ \times \ Cor_{(follow-up-baseline)} \\ &\times \ SD_{baseline} \ \times \ SD_{follow-up}) \end{split}$$

3. Results

3.1. Literature search and study sample characteristics

The search results are displayed in Figure 1. Our search of electronic databases retrieved 3416 records, of which 1060 were duplicates. According to the inclusion and exclusion criteria, 2283 articles were excluded after reading the title and summaries, containing 262 reviews or meta-analyses. We assessed 73 full-text articles, of

which 4 were eligible.^[14,20,21,27] Among the excluded articles, 28 trials were excluded because these are clinical trials lack a control group, 3 studies were excluded because of RCTs or cohort studies that do not meet the purpose of this study, 8 case reports were excluded, and 30 studies were excluded because these belong to the field of basic researches. Table 1 presents the characteristics of the 4 eligible trials involving 208 participants (103 and 105 in the brace group and without brace group, respectively). The trial sample size ranged





Table 1

Basic characteristics of the included trials.

	Sample size	Age (yr)					
Study ID	Brace/No-brace (M/F)	Brace/No-brace	Cervical collar type	Time to immobilization	Intervention	Follow-up	Main outcomes
Cheung 2018 ^[27] China	16 (10/6)/19(10/9)	61.7±14.3/67.2±8.4	Rigid cervical (Philadelphia collar)	3 wk	Open door laminoplasty	1 yr 1, 2, 3, and 6 wk and at 3, 6, and 12 mo postoperatively	VAS, SF-36, and NDI
Overley 2018 ^[21] United States	25/25	55.2±11.72/50.15±9.79	Semirigid cervical orthosis (Miami J cervical orthosis)	6 wk	Instrumented ACDF	1 yr 2 and 6 wk and at 3, 6, and 12 mo postoperatively	NDI
Hida 2017 ^[20] Japan	45(33/12)/45(28/17)	72.0±8.7/71.6±9.6	NA	2 wk	Modified double-door laminoplasty	1 yr 2 wk and at 3, 6, and 12 mo postoperatively	VAS and SF-36
Abbott 2012 ^[14] Sweden	17(9/8)/16(11/5)	53.4±13/47.3±11	Rigid cervical collar (Philadelphia Collar and Camp Scandinavia AB)	6 wk	ACDF	2 yr 6 wk and at 3, 6, 12 and 24 mo postoperatively	NDI, SF-36, and VAS

ID = identification; NA = not applicable; NDI = neck disability index, SF-36 = 36-short form health survey, VAS = Visual Analog Scale.

from 33 to 90 participants. All studies were compared with brace and without brace, 2 of which used rigid brace,^[14,27] 1 for semi-rigid brace,^[21] and 1 did not describe the brace used.^[20] The intervention period is reported between 2 and 6 weeks, of which 2 articles reported 6 weeks with brace after cervical surgery,^[14,27] 1 reported 3 weeks,^[27] and 1 reported 2 weeks.^[20] Two studies used brace for cervical myelopathy undergoing open-door laminoplasty,^[20,27] and 2 other studies used brace after anterior cervical discectomy and fusion. Baseline imbalance was not found in the demographic characteristics or the outcomes between the study groups. Three trials^[20,21,27] reported details of sample size calculations.

3.2. Risk of bias

Figure 2 summarizes the graph of methodological quality. All the included studies described using the computer random method. Three studies showed allocation concealment using

"envelope method."^[14,20,27] And Overley et al's^[21] study did not report it clearly. All studies^[14,20,21,27] either did not use blind methods or did not report it clearly. Only the study by Cheung et al^[27] described using blinding outcome assessment. Three trials^[14,20,27] reported participant losses during follow up period. In addition, the study by Cheung et al^[27] reported all the participants took part in the follow-up.^[27] Selective reporting was difficult to assess in 2 articles^[20,21] because trial protocols were unavailable. All judgments concluded low risk of bias (including incomplete outcome data, no blinding method, and loss to follow-up), suggesting future studies might influence the results in this meta-analysis and require revising the conclusion.

3.3. Meta-analysis outcome

3.3.1. Cervical pain. The cervical pain is shown in Figure 3. Three studies including 158 patients^[14,20,27] reported the result



Figure 2. Risk of bias graph.

		Brace			brace			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.2.1 1 week 22									
Cheung 2018 222	0.8	2.4	16	3.8	3.5	19	4.9%	-3.00 [-4.96, -1.04]	
Subtotal (95% CI)			16			19	4.9%	-3.00 [-4.96, -1.04]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	•) (P = 0	.003)						
1.2.2 2 weeks									
Cheung 2018 ²²	-0.9	3.4	16	1.8	3.2	19	4.3%	-2.70 [-4.90, -0.50]	
Subtotal (95% CI)	-0.9	5.4	16	1.0	5.2	19	4.3%	-2.70 [-4.90, -0.50]	
	nlianhla		10			15	4.0 /0	-2.70 [-4.30, -0.30]	
Heterogeneity: Not ap Test for overall effect:	-	P = 0	02)						
rescior overall effect.	2 - 2.40) (F = 0	.02)						
1.2.3 3 weeks									
Cheung 2018 ²²	-1.2	2.8	16	1.1	0.5	19	7.0%	-2.30 [-3.69, -0.91]	
Subtotal (95% CI)			16			19	7.0%	-2.30 [-3.69, -0.91]	-
Heterogeneity: Not ap	•								
Test for overall effect:	Z = 3.24	+ (P = 0	.001)						
1.2.4 6 weeks									
Abbott 2012 ¹⁴	-2.69	0.3	17	-1.78	1.3	16	10.5%	-0.91 [-1.56, -0.26]	
Cheung 2018 22		2.9	16	-0.5	2.4	19	5.5%	-1.50 [-3.28, 0.28]	
Subtotal (95% CI)	-		33	2.3		35	16.0%	-0.98 [-1.59, -0.37]	◆
Heterogeneity: Tau ² =	0.00: Cł	ni² = 0.3	37. df =	= 1 (P =	0.54):				
Test for overall effect:			-	. (.	0.0.1,				
			,						
1.2.5 3 months									
Abbott 2012 22	-2.24			-1.33	1.1	16	10.6%	-0.91 [-1.52, -0.30]	
Cheung 2018 ²²	-1.1	2.5	16	-0.5	2.4	19	6.1%	-0.60 [-2.23, 1.03]	
Subtotal (95% CI)			33			35	16.7%	-0.87 [-1.44, -0.30]	◆
Heterogeneity: Tau ² =	0.00; Cł	ni² = 0.1	12, df =	= 1 (P =	0.73);	$I^2 = 0\%$	•		
Test for overall effect:	Z = 2.99) (P = 0	.003)						
1.2.6 6 months									
Abbott 2012 ¹⁴	-1.65	0.1	17	-1.93	0.2	16	12.1%	0.28 [0.17, 0.39]	•
Cheung 2018 ²²	-1.5	3	16	-0.8	2.3	19	5.5%	-0.70 [-2.50, 1.10]	
Subtotal (95% CI)			33			35	17.6%	0.22 [-0.25, 0.69]	*
Heterogeneity: Tau ² =	0.06; Cł	ni² = 1.1	14, df =	= 1 (P =	0.29);	l² = 129	%		
Test for overall effect:	Z = 0.91	(P = 0	.36)						
1.2.7 12 months									
Abbott 2012 ¹⁴	-2.75	0.1	17	-1.34	1.1	16	10.9%	-1.41 [-1.95, -0.87]	-
Cheung 2018 ²²	-1.8	3.2	16	-0.5	3.1	19	4.6%	-1.30 [-3.40, 0.80]	<u>-</u>
Hida 2016 ²⁰	-0.19	4.29	45	-0.04	3.54	45	6.1%	-0.15 [-1.78, 1.48]	
Subtotal (95% CI)			78			80	21.6%	-1.26 [-1.81, -0.71]	◆
Heterogeneity: Tau ² =	0.02; Cł	ni² = 2.0)8, df =	= 2 (P =	0.35);	l² = 4%	,	μ. Δ	
Test for overall effect:	Z = 4.51	(P < 0	.00001)					
1.2.8 24 months									
Abbott 2012 ¹⁴	-3.19	0.3	17	-2.37	0.3	16	11.9%	-0.82 [-1.02, -0.62]	•
Subtotal (95% CI)	22		17			16	11.9%	-0.82 [-1.02, -0.62]	♦
Heterogeneity: Not ap	plicable							,	
Test for overall effect:	•	5 (P < 0	.00001)					
rest for overall effect.			242			259	100.0%	-1.06 [-1.63, -0.49]	•
						200	100.070	-1.00 [-1.03, -0.43]	▼
Total (95% CI)	0.60- 04			IF _ 40 4		0004	12 - 0.007		
Total (95% CI) Heterogeneity: Tau² =	,		6.96, c		P < 0.0	00001);	l² = 92%		-4 -2 0 2 4
Total (95% CI)	Z = 3.67	' (P = 0	6.96, c .0002)			,,		_	-4 -2 0 2 4 Favours [Brace] Favours [No brace]

of cervical pain. We performed a subgroup analysis according to different follow-up periods. Pooled analysis showed that postoperative neck brace compared with no brace can relieve neck pain at 1 week, 2 weeks, 3 weeks, 6 weeks, 3 months, 12 months, and 24 months after surgery. The results of the metaanalysis are that -3.00 (-4.96 to -1.04) at the follow-up of 1 week after surgery, -2.70 (-4.90 to -0.50) at the follow-up of 2 weeks after surgery, -2.30 (-3.69 to -0.91) at the follow-up of 3 weeks after surgery, -0.98 (-1.59 to -0.37) at the follow-up of 6 weeks after surgery, -0.87 (-1.44 to -0.30) at the follow-up of 3 months after surgery -1.30 (-1.81 to -0.80) at the follow-up of 12 months after surgery, and -1.26 (-1.81 to -0.71) at the follow-up of 24 months after surgery. However, there was no significant difference between the 2 groups at the follow-up of 6 months (MD, 0.22; 95% CI, [-0.25 to 0.69]).

3.3.2. Neck Disability Index. Three trials^[14,21,27] involving a total of 118 patients reported NDI as an outcome in the groups, as shown in Figure 4. Compared with the nonbrace group, the

Study or Subara		Brace	Tetel		brace	Tatal	Mainht	Mean Difference	Mean Difference
<u>Study or Subgroup</u> 1.1.1 1 week	Mean	<u>SD</u>	rotal	Mean	50	Iotal	weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Cheung 2018 ²²	0.4	04.47	40	40.5	45 7	40	0.70/	44 40 5 05 04 0 041	
Cheung 2018 Subtotal (95% CI)	2.4	24.47	16 16	13.5	15.7	19 19	0.7%	-11.10 [-25.01, 2.81]	
Subtotal (95% CI)	- K b l -		10			19	0.7%	-11.10 [-25.01, 2.81]	
Heterogeneity: Not ap	•	(D - 0)							
Test for overall effect:	Z = 1.56	(P = 0.)	12)						
1.1.2 2 weeks									
Cheung 2018 22	0.2	23.2	16	16	18.12	19	0.7%	-15.80 [-29.79, -1.81]	
Overley 2018		10.79	25		10.57	25	3.5%	5.38 [-0.54, 11.30]	<u> </u>
Subtotal (95% CI)			41			44		-4.22 [-24.89, 16.44]	
Heterogeneity: Tau ² =	194.27;	Chi² = 7	.47, df =	= 1 (P =	0.006);	l² = 879		• • •	
Test for overall effect:	Z = 0.40	(P = 0.6	69)						
1.1.3 3 weeks									
Cheung 2018 22	-3.4	25.8	16	2.1	17.8	19	0.6%	-5.50 [-20.46, 9.46]	
Subtotal (95% CI)	-0.4	20.0	16	2.1	17.0	19	0.6%	-5.50 [-20.46, 9.46]	
Heterogeneity: Not ap	nlicable						0.070	0.00 [20.40, 0.40]	
Test for overall effect:		(P = 0.4)	47)						
		(,						
1.1.4 6 weeks									
Abbott 2012 14	-3.13		17	-0.4	2.7	16	14.7%	-2.73 [-4.23, -1.23]	-
Cheung 2018 22 21		19.64	17		14.53	19	1.1%	-10.00 [-21.40, 1.40]	
Overley 2018	-8.39	15.01		-10.19	13.03	25	2.2%	1.80 [-5.99, 9.59]	
Subtotal (95% CI)			59			60	18.0%	-2.61 [-6.46, 1.24]	
Heterogeneity: Tau² = Test for overall effect:	-			(P = 0.2	24); I² =	30%			
1.1.5 3 months									
Abbott 2012 ¹⁴	-5.81	1	17	-4.43	2.1	16	16.3%	-1.38 [-2.51, -0.25]	-
Cheung 2018 ²²		24.76	17		13.43	19	0.8%	-1.10 [-14.33, 12.13]	
Overley 2018 ²¹		14.64		-12.14		25	2.3%	-0.02 [-7.50, 7.46]	
Subtotal (95% CI)	-12.10	14.04	59	-12.14	12.22	60	19.5%	-1.35 [-2.46, -0.23]	♦
Heterogeneity: Tau ² =	0.00 Ch	$h^2 = 0.13$		(P = 0.9)	24)· I² =		101070		
Test for overall effect:				(i – 0.c	,	070			
1 1 6 6 months									
1.1.6 6 months	o 10					10	47 404	4 40 5 0 40 0 0 0	
Abbott 2012 ¹⁴	-6.42		17	-5.24	1.9	16	17.1%	-1.18 [-2.12, -0.24]	
Cheung 2018 ²² ₂₁		24.91	16		16.65	19	0.7%	-1.50 [-15.82, 12.82]	
Overley 2018	-14.62	13.96	22 55	-14.57	11.58	22	2.3%	-0.05 [-7.63, 7.53]	▲
Subtotal (95% CI)	0.00.04			$(\mathbf{D} - 0)$	261, 12 -	57 0%	20.1%	-1.16 [-2.09, -0.24]	•
Heterogeneity: Tau ² = Test for overall effect:				(P = 0.8	<i>90);</i> 1	0%			
		(,						
1.1.7 12 months	_		. —						_
Abbott 2012 ¹⁴	-7.47		17	-5.14	0.8	16	18.5%	-2.33 [-2.77, -1.89]	•
Cheung 2018 ²²		24.69	16		22.56	19		-2.90 [-18.69, 12.89]	
Overley 2018 ²¹	-16.55	12.54		-15.19	11.6	22	2.5%	-1.36 [-8.50, 5.78]	
Subtotal (95% CI)			55	-		57	21.6%	-2.33 [-2.76, -1.89]	'
Heterogeneity: Tau ² = Test for overall effect:				•	96); ² =	0%			
1.1.8 24 months									
Abbott 2012 ¹⁴	7.04	07	47	0.02		10	15 00/	1 00 [0 60 2 20]	-
	-7.94	2.7	17 17	-9.93	1.1	16	15.2%	1.99 [0.60, 3.38]	la l
Subtotal (95% CI)	olio-k!-		17			16	15.2%	1.99 [0.60, 3.38]	▼
Heterogeneity: Not ap Test for overall effect:		(P = 0.0	005)						
			,						
Total (95% CI)	0.05 5		318	10 (=	0.0000		100.0%	-1.15 [-2.37, 0.08]	
Heterogeneity: Tau ² =				16 (P <	0.00001); ² = 1	70%		-20 -10 0 10 20
	7 = 1.84	(P = 0.0))7)						
Test for overall effect: Test for subaroup diffe			,						Favours [Brace] Favours [No brace]

neck brace group had no statistical significance in terms of NDI within the follow-up of 6 weeks after surgery. The results of the meta- analysis are that -11.10 (-25.01 to 2.81) (MD and 95% CI) at the follow-up of 1 week after surgery, -4.22 (-24.89 to 16.44) at the follow-up of 2 weeks after surgery, -5.50 (-20.46 to 9.46) at the follow-up of 3 weeks after surgery, and -2.61 (-6.46 to 1.24) at the follow-up of 6 weeks after surgery. During the 3 to 12 month follow-up period, the NDI in the cervical brace group was slightly better than the nonbraced group

(-1.35 [-2.46 to -0.23] at 3 months, -1.16 [-2.09 to -0.24] at 6 months, and -2.33 [-2.77 to -1.89] at 12 months). However, 1 study,^[14] only including 33 patients, reported the result of follow-up of 24 months, suggesting tend to get the opposite (1.99 [0.60–3.38]).

3.3.3. SF-36 (Physical Component Summary scale). Three studies^[14,20,27] involving a total of 158 patients showed the SF-36 Physical Component Summary scale (PCS) with cervical brace

and nonbrace after cervical surgery (see Fig. 5). In the early 3 weeks after surgery, there was no significant difference between the cervical brace group and the nonbraced group (2.90 [-2.23 to 8.03] at 1 week, 6.40 [-0.14 to 12.94] at 2 weeks, and 3.40 [-3.57 to 10.37] at 3 weeks). During the 6 week to 24 month follow-up period, the SF-36 (PCS) in the cervical brace group was better than the nonbraced group (5.04 [4.26–5.82] at 6 weeks, 4.83 [4.01–5.66] at 3 months, 5.18 [0.70–9.67] at 6 months, 5.09 [4.27–5.92] at 12 months, and 1.83 [1.45–2.21] at 24 months).

3.3.4. SF-36 (Mental Component Summary scale). As shown in Figure 6, of the 4 RCTs reporting using brace after cervical surgery, 3 studies^[14,20,27] explicitly stated the SF-36 (Mental Component Summary scale [MCS] scale) result involving a total of 158 patients. According to different follow-up times, the results are that (MD and 95% CI) 4.90 (-2.01 to 11.81) at 1 week, 6.20 (-0.89 to 13.29) at 2 weeks, 6.00 (-1.09 to 13.09) at 3 weeks, 0.45 (-0.40 to 1.30) at 6 weeks, -0.25 (-5.36 to 4.85) at 3 months, 0.25(-0.81 to 1.30) at 6 months, 1.78 (-1.58 to 35.14) at 12 months, and 1.75 (-2.76 to 6.26) at 24 months.

tudy or Subgroup		Brace			brace			Mean Difference	Mean Difference
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
.3.1 1 week 22									
cheung 2018	0.8	7.09	16	-2.1	8.39	19	5.3%	2.90 [-2.23, 8.03]	
ubtotal (95% CI)			16			19	5.3%	2.90 [-2.23, 8.03]	•
eterogeneity: Not a	plicable								
est for overall effect	-	(P = 0.1)	27)						
.3.2 2 weeks									
heung 2018 ²²	3.8	10.66	16	-2.6	8.77	19	3.8%	6.40 [-0.14, 12.94]	— —
ubtotal (95% CI)	0.0		16		•	19	3.8%	6.40 [-0.14, 12.94]	◆
leterogeneity: Not a	onlicable								
est for overall effect	•	$(\mathbf{P} = 0)$	06)						
	. Z = 1.92	(F = 0.	00)						
.3.3 3 weeks									
heung 2018 ²²		44.0	40		0.40	40	0.50/	0 40 1 0 57 40 071	
•	4.4	11.9	16	1	8.48	19 19	3.5%	3.40 [-3.57, 10.37]	
ubtotal (95% CI)			16			19	3.5%	3.40 [-3.57, 10.37]	
leterogeneity: Not a	•	-	• • •						
est for overall effect	: Z = 0.96	(P = 0.)	34)						
240									
.3.4 6 weeks									_
bbott 2012 14	6.04	1.1	17	0.98	1.2	16	13.7%	5.06 [4.27, 5.85]	■
cheung 2018 22	6.4	9.36	16	2.8	8.77	19	4.3%	3.60 [-2.45, 9.65]	
ubtotal (95% CI)			33			35	18.0%	5.04 [4.26, 5.82]	•
leterogeneity: Tau ² =	= 0.00; Ch	i ² = 0.2	2, df =	1 (P = 0).64); l ^a	² = 0%			
est for overall effect	: Z = 12.6	5 (P < 0	0.00001)					
.3.5 3 months									
bbott 2012 ¹⁴	7.2	0.6	17	2.32	1.6	16	13.6%	4.88 [4.05, 5.71]	•
cheung 2018 ²²	6.7	8.86	17		8.74	19	4.6%	2.60 [-3.16, 8.36]	
Subtotal (95% CI)	0.1	0.00	34		0.7 1	35	18.2%	4.83 [4.01, 5.66]	♦
leterogeneity: Tau ² =	= 0 00· Ch	$i^2 = 0.5$		1 (P = 0)	1 4 A) · 12				
		- 0.0	3, ui –	U	·.++), I	- 070			
est for overall effect		7 (P < 0	0.00001)					
est for overall effect		7 (P < 0	0.00001)					
est for overall effect		7 (P < 0	0.00001	,					
est for overall effect .3.6 6 months .bbott 2012 ¹⁴		7 (P < 0 0.1).00001 17) 3.24	3	16	12.5%	6.78 [5.31, 8.25]	-
est for overall effect	: Z = 11.4	,		3.24	3 9.26	16 19	12.5% 4.5%	6.78 [5.31, 8.25] 1.90 [-3.91, 7.71]	
est for overall effect .3.6 6 months .bbott 2012 ¹⁴	: Z = 11.4 10.02	0.1	17	3.24					-
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ Cheung 2018 ²²	: Z = 11.4 10.02 7.5	0.1 8.53	17 17 34	3.24 5.6	9.26	19 35	4.5% 17.0%	1.90 [-3.91, 7.71]	
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ Cheung 2018 ²² Subtotal (95% CI)	: Z = 11.4 10.02 7.5 = 7.23; Ch	0.1 8.53 ii² = 2.5	17 17 34 5, df =	3.24 5.6	9.26	19 35	4.5% 17.0%	1.90 [-3.91, 7.71]	
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ cheung 2018 ²² Subtotal (95% CI) leterogeneity: Tau ² =	: Z = 11.4 10.02 7.5 = 7.23; Ch	0.1 8.53 ii² = 2.5	17 17 34 5, df =	3.24 5.6	9.26	19 35	4.5% 17.0%	1.90 [-3.91, 7.71]	
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ .beung 2018 ²² subtotal (95% CI) leterogeneity: Tau ² = est for overall effect .3.7 12 months	: Z = 11.4 10.02 7.5 = 7.23; Ch	0.1 8.53 ii² = 2.5	17 17 34 5, df =	3.24 5.6	9.26	19 35	4.5% 17.0%	1.90 [-3.91, 7.71]	•
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ cheung 2018 ²² subtotal (95% CI) leterogeneity: Tau ² = fest for overall effect	: Z = 11.4 10.02 7.5 = 7.23; Ch	0.1 8.53 ii² = 2.5	17 17 34 5, df =	3.24 5.6	9.26	19 35	4.5% 17.0%	1.90 [-3.91, 7.71]	•
test for overall effect .3.6 6 months .bbott 2012 ¹⁴ .bbott 2012 ²² Subtotal (95% CI) leterogeneity: Tau ² = iest for overall effect .3.7 12 months .bbott 2012 ¹⁴ .2.2	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26	0.1 8.53 ii² = 2.5 (P = 0.1	17 17 34 5, df = 02)	3.24 5.6 1 (P = 0 3.5	9.26).11); l [:]	19 35 ² = 61%	4.5% 17.0%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67]	•
est for overall effect .3.6 6 months bbott 2012 ¹⁴ beung 2018 ²² ubtotal (95% CI) leterogeneity: Tau ² = est for overall effect .3.7 12 months bbott 2012 ¹⁴ .22 theung 2018 ²²	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2	0.1 8.53 ii ² = 2.5 (P = 0.0 0.6 8.53	17 17 34 5, df = 02) 17 17	3.24 5.6 1 (P = 0 3.5 6.3	9.26).11); l [;] 1.6 9.35	19 35 2 = 61% 16 19	4.5% 17.0% 13.6% 4.5%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74]	•
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ .beung 2018 ²² subtotal (95% CI) leterogeneity: Tau ² = .est for overall effect .3.7 12 months .bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²²	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2	0.1 8.53 ii ² = 2.5 (P = 0.1 0.6	17 17 34 5, df = 02) 17	3.24 5.6 1 (P = 0 3.5 6.3	9.26).11); l ^a 1.6	19 35 ² = 61% 16	4.5% 17.0% 13.6% 4.5% 1.9%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29]	
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ .beung 2018 ²² .bubtotal (95% CI) leterogeneity: Tau ² = .est for overall effect .3.7 12 months .bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²²	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5	0.1 8.53 ii ² = 2.5 (P = 0.1 0.6 8.53 23.92	17 17 34 5, df = 02) 17 17 45 79	3.24 5.6 1 (P = 0 3.5 6.3 1.4	9.26).11); l ² 1.6 9.35 25.4	19 35 2 = 61% 16 19 45 80	4.5% 17.0% 13.6% 4.5%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74]	
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ .beung 2018 ²² .bubtotal (95% CI) leterogeneity: Tau ² = .est for overall effect .3.7 12 months .bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²²	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch	0.1 8.53 $ii^2 = 2.53$ (P = 0.1 0.6 8.53 23.92 $ii^2 = 1.10$	17 34 5, df = 02) 17 45 79 0, df =	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26).11); l ² 1.6 9.35 25.4	19 35 2 = 61% 16 19 45 80	4.5% 17.0% 13.6% 4.5% 1.9%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29]	•
est for overall effect .3.6 6 months bbott 2012 ¹⁴ cheung 2018 ²² ubtotal (95% CI) leterogeneity: Tau ² = fest for overall effect .3.7 12 months bbott 2012 ¹⁴ .cheung 2018 ²² lida 2016 ubtotal (95% CI) leterogeneity: Tau ² = fest for overall effect	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch	0.1 8.53 $ii^2 = 2.53$ (P = 0.1 0.6 8.53 23.92 $ii^2 = 1.10$	17 34 5, df = 02) 17 45 79 0, df =	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26).11); l ² 1.6 9.35 25.4	19 35 2 = 61% 16 19 45 80	4.5% 17.0% 13.6% 4.5% 1.9%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29]	•
est for overall effect .3.6 6 months .bbott 2012 ¹⁴ .cheung 2018 ²² .ubtotal (95% CI) leterogeneity: Tau ² = fest for overall effect .3.7 12 months .bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²² .cheung 2016 .ubtotal (95% CI) leterogeneity: Tau ² = fest for overall effect .3.8 24 months	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1	0.1 8.53 (P = 0.1 0.6 8.53 23.92 ii ² = 1.11 2 (P < 0	17 17 34 5, df = 02) 17 17 45 79 0, df = 1 0.00001	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26 0.11); l ² 1.6 9.35 25.4 0.58); l ²	19 35 2 = 61% 16 19 45 80 2 = 0%	4.5% 17.0% 13.6% 4.5% 1.9% 20.0%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92]	
ast for overall effect .3.6 6 months .bbott 2012 ¹⁴ .bbott 2012 ¹⁴ .bbott 2012 ¹² .bbott 2018 ²² .bbott 2018 ²² .cbeung 2018 ²	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch	0.1 8.53 $ii^2 = 2.53$ (P = 0.1 0.6 8.53 23.92 $ii^2 = 1.10$	17 17 34 5, df = 02) 17 17 79 0, df = 1 0.00001	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26).11); l ² 1.6 9.35 25.4	19 35 2 = 61% 16 19 45 80 2 = 0%	4.5% 17.0% 13.6% 4.5% 1.9% 20.0%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92]	
ast for overall effect a.3.6 6 months bbott 2012 ¹⁴ bchung 2018 ²² bubtotal (95% CI) leterogeneity: Tau ² = est for overall effect a.3.7 12 months bbott 2012 ¹⁴ bbott 2018 ²² cheung 2018 ²² bida 2016 bibtotal (95% CI) leterogeneity: Tau ² = est for overall effect a.3.8 24 months bbott 2012 ¹⁴ bubtotal (95% CI)	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1 8.11	0.1 8.53 (P = 0.1 0.6 8.53 23.92 ii ² = 1.11 2 (P < 0	17 17 34 5, df = 02) 17 17 45 79 0, df = 1 0.00001	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26 0.11); l ² 1.6 9.35 25.4 0.58); l ²	19 35 2 = 61% 16 19 45 80 2 = 0%	4.5% 17.0% 13.6% 4.5% 1.9% 20.0%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92]	
ast for overall effect a.3.6 6 months bbott 2012 ¹⁴ bbott 2012 ¹⁴ bbott 2012 ¹² bubtotal (95% CI) leterogeneity: Tau ² = est for overall effect a.3.7 12 months bbott 2012 ¹⁴ bbott 2018 ²² cheung 2018 ²² bida 2016 bbott 2012 ¹⁴ cest for overall effect a.3.8 24 months bbott 2012 ¹⁴ bubtotal (95% CI) leterogeneity: Not ag	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1 8.11 oplicable	0.1 8.53 (P = 0.0) 0.6 8.53 23.92 $h^2 = 1.10$ 2 (P < 0 0.8	17 17 34 5, df = 02) 17 17 79 0, df = 1 0.00001 17 17 17	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26 0.11); l ² 1.6 9.35 25.4 0.58); l ²	19 35 2 = 61% 16 19 45 80 2 = 0%	4.5% 17.0% 13.6% 4.5% 1.9% 20.0%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92]	
ast for overall effect a.3.6 6 months bbott 2012 ¹⁴ bbott 2012 ¹⁴ bbott 2012 ¹² bubtotal (95% CI) leterogeneity: Tau ² = est for overall effect a.3.7 12 months bbott 2012 ¹⁴ bbott 2018 ²² cheung 2018 ²² bida 2016 bbott 2012 ¹⁴ cest for overall effect a.3.8 24 months bbott 2012 ¹⁴ bubtotal (95% CI) leterogeneity: Not ag	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1 8.11 oplicable	0.1 8.53 (P = 0.0) 0.6 8.53 23.92 $h^2 = 1.10$ 2 (P < 0 0.8	17 17 34 5, df = 02) 17 17 79 0, df = 1 0.00001 17 17 17	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26 0.11); l ² 1.6 9.35 25.4 0.58); l ²	19 35 2 = 61% 16 19 45 80 2 = 0%	4.5% 17.0% 13.6% 4.5% 1.9% 20.0%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92]	
ast for overall effect .3.6 6 months .bbott 2012 ¹⁴ .beung 2018 ²² Bubtotal (95% CI) leterogeneity: Tau ² = east for overall effect .3.7 12 months .bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²³ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁶ .cheung 2018 ²⁶ .cheung 2018 ²⁶ .cheung 2018 ²⁷ .cheung 2018 ²⁷	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1 8.11 oplicable	0.1 8.53 (P = 0.0) 0.6 8.53 23.92 $h^2 = 1.10$ 2 (P < 0 0.8	17 17 34 5, df = 02) 17 17 45 79 0, df = 0.00001	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0	9.26 0.11); l ² 1.6 9.35 25.4 0.58); l ²	19 35 2 = 61% 16 19 45 80 2 = 0% 16 16	4.5% 17.0% 13.6% 4.5% 1.9% 20.0% 14.1%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92] 1.83 [1.45, 2.21] 1.83 [1.45, 2.21]	
ast for overall effect .3.6 6 months .bott 2012 ¹⁴ .beung 2018 ²² Bubtotal (95% CI) leterogeneity: Tau ² = east for overall effect .3.7 12 months .bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²³ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁶ .cheung 2018 ²⁶ .cheung 2018 ²⁶ .cheung 2018 ²⁷ .cheung 2018 ²⁷	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1 8.11 oplicable : Z = 9.35	0.1 8.53 $ii^2 = 2.5:$ (P = 0.1) 0.6 8.53 23.92 $ii^2 = 1.1i^2$ 2 (P < 0.1) 0.8 (P < 0.1)	17 17 34 5, df = 02) 17 17 45 79 0, df = 1 0.00001 17 17 00001) 245	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0) 6.28	9.26 0.11); F 9.35 25.4 0.58); F	19 35 2 = 61% 16 19 45 80 2 = 0% 16 16 16 258	4.5% 17.0% 13.6% 4.5% 1.9% 20.0% 14.1% 14.1%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92]	
est for overall effect .3.6 6 months bbott 2012 ¹⁴ .beung 2018 ²² ubtotal (95% CI) leterogeneity: Tau ² = est for overall effect .3.7 12 months bbott 2012 ¹⁴ .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²² .cheung 2018 ²³ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁴ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁵ .cheung 2018 ²⁶ .cheung 2018 ²⁶ .cheung 2018 ²⁶ .cheung 2018 ²⁷ .cheung 2018 ²⁷ .ch	: Z = 11.4 10.02 7.5 = 7.23; Ch : Z = 2.26 8.65 10.2 1.5 = 0.00; Ch : Z = 12.1 8.11 pplicable : Z = 9.35 = 4.14; Ch	0.1 8.53 $ii^2 = 2.5:$ (P = 0.1) 0.6 8.53 23.92 $ii^2 = 1.12$ 2 $(P < 0.2)$ 0.8 (P < 0.1) $ii^2 = 1.31$	17 17 34 5, df = 02) 17 17 45 79 0, df = 0.00001 17 17 00001) 245 1.32, df	3.24 5.6 1 (P = 0 3.5 6.3 1.4 2 (P = 0) 6.28 = 12 (P	9.26 0.11); F 9.35 25.4 0.58); F	19 35 2 = 61% 16 19 45 80 2 = 0% 16 16 16 258	4.5% 17.0% 13.6% 4.5% 1.9% 20.0% 14.1% 14.1%	1.90 [-3.91, 7.71] 5.18 [0.70, 9.67] 5.15 [4.32, 5.98] 3.90 [-1.94, 9.74] 0.10 [-10.09, 10.29] 5.09 [4.27, 5.92] 1.83 [1.45, 2.21] 1.83 [1.45, 2.21]	

Figure 5. Forest plot and meta-analysis of SF-36 (PCS). CI = confidence interval, PCS = Physical Component Summary, SD = standard deviation, SF = 36-short form health survey.

Medicine

Study or Subgroup	B Mean	Brace SD	Total	No Mean	o brace SD	Total	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV. Random, 95% Cl
1.4.1 1 week Cheung 2018 22	1.7	10.45	16	-3.2	10.32	19	3.6%	4.90 [-2.01, 11.81]	
Subtotal (95% CI)			16			19	3.6%	4.90 [-2.01, 11.81]	
Heterogeneity: Not app Test for overall effect:		(P = 0.1	16)						
1.4.2 2 weeks Cheung 2018 ²²	А	10.95	16	-22	10.32	19	3.5%	6.20 [-0.89, 13.29]	
Subtotal (95% CI)	-	10.35	16	-2.2	10.52	19	3.5%	6.20 [-0.89, 13.29]	
Heterogeneity: Not app Test for overall effect:		(P = 0.0	09)						
1.4.3 3 weeks									
Cheung 2018 22	3.7	10.84	16	-2.3	10.44	19	3.5%	6.00 [-1.09, 13.09]	
Subtotal (95% CI)	liaabla		16			19	3.5%	6.00 [-1.09, 13.09]	
Heterogeneity: Not app Test for overall effect:		(P = 0.1	10)						
1.4.4 6 weeks									
Abbott 2012 ¹⁴	1.94	1.8	17	1.54	0.1	16	15.8%	0.40 [-0.46, 1.26]	
Cheung 2018	4.1	11.6	16 33	0	10.65	19 35	3.2% 19.1%	4.10 [-3.33, 11.53] 0.45 [-0.40, 1.30]	•
Heterogeneity: Tau ² =	0.00: Chi	² = 0.94		1 (P = 0).33): l² =		19.170	0.40 [-0.40, 1.30]	ſ
Test for overall effect:	,		,	. (. – 0		0,0			
1.4.5 3 months									
Abbott 2012 14	4.19	0.6	17	6.16	1.3	16	16.1%	-1.97 [-2.67, -1.27]	-
Cheung 2018 22	2.8	10.42	16	-0.9	10.69	19	3.6%	3.70 [-3.31, 10.71]	
Subtotal (95% CI)	0.64. 04	2 - 0 40	33		44\.12-	35	19.7%	-0.25 [-5.36, 4.85]	
Heterogeneity: Tau ² = Test for overall effect:	-		-	I (P = 0).11); 1-=	= 60%			
1.4.6 6 months									
Abbott 2012 14	5.01	1.4	17	4.69	1.7	16	15.4%	0.32 [-0.75, 1.39]	<u>†</u>
Cheung 2018 ²²	-0.7	10.95	16	2.2	10.24	19	3.5%	-2.90 [-9.97, 4.17]	
Subtotal (95% CI) Heterogeneity: Tau ² =	0 00· Chi	2 – 0 79	33 adf = -	1 (P - 0	1 38\· I2 -	35 - 0%	18.9%	0.25 [-0.81, 1.30]	T
Test for overall effect:				Г (F – С	<i></i>	- 0 /8			
1.4.7 12 months									
Abbott 2012 ¹⁴ Cheung 2018 ²²	5.14	0.6	17	1.95	3.1	16	14.2%	3.19 [1.64, 4.74]	
Hida 2016	6.6 0.1	11.46 8.96	16 45		10.41 10.37	19 45	3.3% 7.6%	3.80 [-3.51, 11.11] -1.50 [-5.50, 2.50]	
Subtotal (95% CI)	0.1	0.00	78	1.5	10.07	80	25.1%	1.78 [-1.58, 5.14]	◆
Heterogeneity: Tau ² = Test for overall effect: 2				2 (P = 0).10); l² =	= 57%		_ * *	
1.4.8 24 months									
Abbott 2012 ¹⁴ Subtotal (95% CI)	7.44	5.2	17 17	5.69	7.7	16 16	6.6% 6.6%	1.75 [-2.76, 6.26] 1.75 [-2.76, 6.26]	•
Heterogeneity: Not app Test for overall effect:		(P = 0.4	45)					4	
1.4.9 New Subgroup			-			-		N	
Subtotal (95% CI)	licoblo		0			0		Not estimable	
Heterogeneity: Not app Test for overall effect:		cable							
Total (95% CI)			242				100.0%	1.14 [-0.35, 2.64]	▶
Heterogeneity: Tau ² =				12 (P ·	< 0.0000	1); l² =	80%	-	-20 -10 0 10 20
Test for overall effect: Test for subaroup diffe			,	- 7 /D -	- 0 38/	2 - 6 4	0/_		Favours [No brace] Favours [Brace]
									nt Summary, SD = standard deviation, SF-36 = 36

Figu ort form health survey.

Therefore, SF-36 (MCS) does not change significantly in the brace group or the nonbrace group at any time after surgery.

3.3.5. Grading of recommendations assessment, development, and evaluation. The GRADE level of evidence is moderate for all of the results. Table 2 shows the GRADE evidence profiles. The main reason for the decreasing level was small sample size.

3.3.6. Publication bias. For the same outcome, the number of included trials (<10) was too small to conduct any sufficient additional analysis of publication bias.

Table 2	
The GRADE evidence of outcomes.	

Outcomes	No. of participants (studies)	Certainty of the evidence (GRADE)
NDI follow-up: range 2 wk to 24 mo	112(3 RCTs)	⊕⊕⊕○ MODERATE*
SF-36 (PCS) follow-up: range 2 wk to 24 mo	142(3 RCTs)	⊕⊕⊕○ MODERATE*
Neck pain follow-up: range 1 wk to 24 mo	142(3 RCTs)	⊕⊕⊕○ MODERATE*
SF-36 (MCS) follow-up: range 1 wk to 24 mo	142(3 RCTs)	⊕⊕⊕○ MODERATE*

 $\label{eq:GRADE} GRADE = \mbox{Grading of Recommendations Assessment, Development, and Evaluation, MCS = Mental Component Summary, NDI = neck disability index, PCS = Physical Component Summary, RCT = randomized controlled trial, SF-36 = 36-short form health survey.$

*Sample size is small.

4. Discussion

To the best of our knowledge, this is the first meta-analysis that provides comprehensive and quantitative evidence for postoperative cervical spine with and without cervical brace. In addition, the purpose of this study was to examine the pain, functional outcome, and quality of life with the 2 methods of postoperative management. In this meta-analysis of 4 trials, 208 patients were included. Overall, we found that postoperative use of the cervical brace can relieve cervical pain slightly and partially improve NDI and SF-36 (PCS) and intermittently showed statistically significant improvements. However, for SF-36 (MCS), there was no significant difference between the braced group and the nonbraced group.

Postoperative cervical pain typified by persistent pain around the neck and shoulders is a common problem associated with cervical laminoplasty and anterior cervical decompression and fusion.^[28-30] Although the exact cause of axial neck pain has not been detected, intraoperative invasion to the cervical muscles is presumed to be involved in this complication.[30-32] External cervical brace can limit cervical activity. The use of rigid cervical neck collars has been shown to reduce the usual cervical range of motion by 62.9%,^[33] which may promote the repair of neck tissue,^[34] so it is a possible cause of pain relief. In the present research, postoperative use of the cervical brace can relieve cervical pain compared with no neck brace during the 24-month follow-up period. Only in the 6 months after surgery, the braced group shows no advantage in relieving cervical pain. At the same time, the advantage of wearing a neck brace to relieve neck pain tends to decline over time(-3 for 1 week, -2.7 for 2 weeks, -2.3 for 3 weeks, -0.98 for 6 weeks, -0.87 for 3 weeks, -1.3 for 12 months, and -1.07 for 24 months). Furthermore, to evaluate treatment effectiveness, Carreon et al^[35] have reported the minimal clinical important difference (MCID) for pain to be 2.5. Therefore, the pain relief in only 2 weeks with and without neck brackets has clinical significance. The research by Ebata et al^[36] showed that the postoperative neck pain of patients wearing cervical brace scores significantly reduced at 2 weeks following cervical laminoplasty surgery, which is similar to our results. In addition, according to a questionnaire study sampling spine surgeons, 63% of spine surgeons employed routine postoperative cervical bracing following surgery may be due to improving pain relief.[37]

We used NDI to evaluate cervical function. Braced group for 3, 6, and 12 months could reduce the NDI, but there was reversed result for 24 months. Actually, only the study by Abbott et al^[14] in all the literature included in this meta-analysis showed that nonbraced group was slightly better in NDI than braced group at 24 months. In addition, the author reported more than 50% loss to follow-up in NDI outcome measures at 24 months. Therefore, this study outcome should be interpreted with caution. According to the study by Carreon et al,^[35] MCID for NDI is 7.5, so for the outcome of NDI in this study, although there are statistical differences in the improvement of cervical brace wearing after cervical surgery, there is no clinical significance.

With regard to the quality of life, both procedures were found to be associated with significant improvement in SF-36 (PCS) compared with baseline. Additional, we found a statistically significant difference of 5.04 points, 4.83 points, 5.18 points, 5.1 points, and 1.83 points for SF-36 (PCS) in favor of the braced group from 6 weeks to 24 months, clinical significance exists except for 24 months in line with the study by Carreon et al,^[35] and MCID for SF-36 (PCS) is 4.1. However, no association between postoperative cervical brace and SF-36 (MCS) was seen in our study. This study was able to identify that the use of cervical brace can be associated with the improvement of SF-36 (PCS) at 6 weeks after operation and may be related to the early cervical vertebral movement restriction, which is beneficial to the healing of the incision and the fusion of vertebral, so as to relieve the preoperative symptoms better. Similarly, in the study by Campbell et al,^[13] significant improvements in SF-36 (PCS) were seen at the follow-up period of 6 to 24 months for cervical braced group. SF-36 (MCS) is related to mental health, and there appears to be no significant change at all time intervals. However, the patients wearing neck brace in the first 3 weeks after operation have a tendency to improve SF-36 (MCS), which may be concerned with additional treatment of neck brace. The patients get some psychological comfort. From 6 weeks after the surgery, the neck brace was released during this time, and psychological factors were eliminated. Therefore, the improvement in the trend of SF-36 (MCS) has also disappeared.

There were some potential limitations. First, the test power was limited by sample size. Only 4 studies were included in this meta-analysis, and all of them had a relatively small sample size (n < 100) although all the literature from 8 databases is RCTs, which are considered as highly reliable and evidence-based study designs. Therefore, the GRADE shows a moderate level of evidence in all results, and the main reason for the downgrade is the small sample size. Second, the included studies in this meta-analysis were performed in different patient groups, different cervical surgical procedures, different braces, and various clinical settings. Therefore, the risk of introducing potential heterogeneity is present. Finally, publication bias will have influenced results to some degree, but the number of included trials (<10) for the same outcome was too small to conduct any sufficient additional analysis of publication bias. However, we strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to improve the quality of this systematic review and meta-analysis.

5. Conclusions

The limited existing literature does seem to suggest that wearing cervical brace helps relieve pain. In addition, the improvement of cervical function by brace is mainly from 3 to 12 months after surgery. As for the quality of life, cervical brace is recommended to improve the state of physical health from 6 weeks to 24 months. However, there is no relevant evidence indicating whether cervical brace is an option for mental health of patients. Besides, the evidence of all results is moderate. More higher quality randomized studies are needed to verify the current conclusions.

Author contributions

The study was conceptualized by ZHF, and MY, MY, and JDZ searched and selected the trials, and extracted, analyzed, and interpreted the data. MY drafted the article. ZHF and JDZ helped with the study design and critically reviewed the article. All authors read and approved the final version of the article.

References

- Cohen SP. Epidemiology, diagnosis, and treatment of neck pain. Mayo Clin Proc 2015;90:284–99.
- [2] Neck pain guidelines: revision 2017: using the evidence to guide physical Therapist Practice. J Orthop Sports Phys Ther 2017;47:511–2.
- [3] Hoy D, March L, Woolf A, et al. The global burden of neck pain: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1309–15.
- [4] Cohen SP, Hooten WM. Advances in the diagnosis and management of neck pain. BMJ 2017;358:j3221.
- [5] Yonenobu K. Cervical radiculopathy and myelopathy: when and what can surgery contribute to treatment? Eur Spine J 2000;9:1–7.
- [6] Lee DH, Cho JH, Hwang CJ, et al. Multilevel posterior foraminotomy with laminoplasty versus laminoplasty alone for cervical spondylotic myelopathy with radiculopathy: a comparative study. Spine J 2018;18:414–21.
- [7] Lee DH, Cho JH, Hwang CJ, et al. Multilevel posterior foraminotomy with laminoplasty versus laminoplasty alone for cervical spondylotic myelopathy with radiculopathy: a comparative study. Spine J 2018;18:414–21.
- [8] Okazaki T, Nakagawa H, Mure H, et al. Microdiscectomy and foraminotomy in cervical spondylotic myelopathy and radiculopathy. Neurol Med Chir (Tokyo) 2018;58:468–76.
- [9] Turner I, Choi D. NuNec[™] cervical disc arthroplasty improves quality of life in cervical radiculopathy and myelopathy: a 2-yr follow-up. Neurosurgery 2018;83:422-8.
- [10] McConnell JR, Freeman BJ, Debnath UK, et al. A prospective randomized comparison of coralline hydroxyapatite with autograft in cervical interbody fusion. Spine (Phila Pa 1976) 2003;28:317–23.
- [11] Jagannathan J, Shaffrey CI, Oskouian RJ, et al. Radiographic and clinical outcomes following single-level anterior cervical discectomy and allograft fusion without plate placement or cervical collar. J Neurosurg Spine 2008;8:420–8.
- [12] Wen Z, Lu T, Wang Y, et al. Anterior cervical corpectomy and fusion and anterior cervical discectomy and fusion using titanium mesh cages for treatment of degenerative cervical pathologies: a literature review. Med Sci Monit 2018;24:6398–404.
- [13] Campbell MJ, Carreon LY, Traynelis V, et al. Use of cervical collar after single-level anterior cervical fusion with plate: is it necessary? Spine (Phila Pa 1976) 2009;34:43–8.
- [14] Abbott A, Halvorsen M, Dedering A. Is there a need for cervical collar usage post anterior cervical decompression and fusion using interbody cages? A randomized controlled pilot trial. Physiother Theory Pract 2013;29:290–300.
- [15] .Webber-Jones JE, Thomas CA, Bordeaux RE Jr. The management and prevention of rigid cervical collar complications. Orthop Nurs 2002;21:19–25.
- [16] Miller CP, Bible JE, Jegede KA, et al. The effect of rigid cervical collar height on full, active, and functional range of motion during fifteen activities of daily living. Spine (Phila Pa 1976) 2010;35:E1546–52.
- [17] Connolly PJ, Grob D. Bracing of patients after fusion for degenerative problems of the lumbar spine--yes or no? Spine (Phila Pa 1976) 1998;23:1426–8.
- [18] Camara R, Ajayi OO, Asgarzadie F. Are external cervical orthoses necessary after anterior cervical discectomy and fusion: a review of the literature. Cureus 2016;8:e688.
- [19] Lu F, Wang H, Jiang J, et al. Efficacy of anterior cervical decompression and fusion procedures for monomelic amyotrophy treatment: a prospective randomized controlled trial: clinical article. J Neurosurg Spine 2013;19:412–9.

- [20] Hida T, Sakai Y, Ito K, et al. Collar fixation is not mandatory after cervical laminoplasty: a randomized controlled trial. Spine (Phila Pa 1976) 2017;42:E253–9.
- [21] Overley SC, Merrill RK, Baird EO, et al. Is cervical bracing necessary after one- and two-level instrumented anterior cervical discectomy and fusion? A prospective randomized study. Global Spine J 2018;8:40–6.
- [22] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
- [23] Furlan AD, Malmivaara A, Chou R, et al. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015;40:1660–73.
- [24] Higgins JPT; GSe. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org/; http://www.cochrane-handbook.org.
- [25] Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.
- [26] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
- [27] Cheung JPY, Cheung PWH, Law K, et al. Postoperative rigid cervical collar leads to less axial neck pain in the early stage after opendoor laminoplasty-a single-blinded randomized controlled trial. Neurosurgery 2019;85:325–34.
- [28] Mori E, Ueta T, Maeda T, et al. Effect of preservation of the C-6 spinous process and its paraspinal muscular attachment on the prevention of postoperative axial neck pain in C3-6 laminoplasty. J Neurosurg Spine 2015;22:221–9.
- [29] Hosono N, Sakaura H, Mukai Y, et al. The source of axial pain after cervical laminoplasty-C7 is more crucial than deep extensor muscles. Spine (Phila Pa 1976) 2007;32:2985–8.
- [30] Faour M, Anderson JT, Haas AR, et al. Neck pain, preoperative opioids, and functionality after cervical fusion. Orthopedics 2017;40:25–32.
- [31] Kotani Y, Abumi K, Ito M, et al. Minimum 2-year outcome of cervical laminoplasty with deep extensor muscle-preserving approach: impact on cervical spine function and quality of life. Eur Spine J 2009;18:663–71.
- [32] Otani K, Sato K, Yabuki S, et al. A segmental partial laminectomy for cervical spondylotic myelopathy: anatomical basis and clinical outcome in comparison with expansive open-door laminoplasty. Spine (Phila Pa 1976) 2009;34:268–73.
- [33] Whitcroft KL, Massouh L, Amirfeyz R, et al. Comparison of methods of measuring active cervical range of motion. Spine (Phila Pa 1976) 2010;35:E976–80.
- [34] Hettrich CM, Gasinu S, Beamer BS, et al. The effect of mechanical load on tendon-to-bone healing in a rat model. Am J Sports Med 2014;42:1233–41.
- [35] Carreon LY, Glassman SD, Campbell MJ, et al. Neck disability index, short form-36 physical component summary, and pain scales for neck and arm pain: the minimum clinically important difference and substantial clinical benefit after cervical spine fusion. Spine J 2010;10:469–74.
- [36] Ebata S, Sato H, Ohba T, et al. Postoperative intervertebral stabilizing effect after cervical laminoplasty. J Back Musculoskelet Rehabil 2015;28:303–9.
- [37] Bible JE, Biswas D, Whang PG, et al. Postoperative bracing after spine surgery for degenerative conditions: a questionnaire study. Spine J 2009;9:309–16.